Financial Data and Key Metrics Changes - The company reported fourth quarter sales of $576 million, reflecting a 3% increase year-over-year on a reported basis and 2% organic growth [12] - For the full year, sales reached $2.2 billion, representing a 7% reported growth, with organic growth of 6% [12][13] - Adjusted gross margins improved to 61%, an increase of 170 basis points, while adjusted EBITDA margin remained flat at 17.9% [13][17] - Adjusted earnings per share rose to $3.30, up 16% due to gross margin expansion and reduced interest expenses [13] Business Line Data and Key Metrics Changes - The Recon segment achieved 8% organic growth, while the Prevention and Recovery (PNR) segment grew 4% organically [7][12] - In the fourth quarter, Recon grew 3% and PNR was flat, impacted by four fewer selling days compared to the previous year [8] - U.S. Recon experienced 6% organic growth in 2025, driven by double-digit growth in extremities and shoulders [8][9] - Internationally, Recon grew 10% organically, with high single-digit growth in hips and knees [9] Market Data and Key Metrics Changes - The overall market for PNR is believed to be growing closer to 2%, while the company achieved 4% organic growth in this segment [7] - The company noted that the U.S. hip and knee business is expected to see growth driven by new product launches and competitive conversions [9][16] Company Strategy and Development Direction - The company is focused on three key priorities: commercial execution, operational excellence, and financial discipline [5] - A "One Enovis" operating mindset is being embraced to improve performance and standardize processes across the organization [6] - The company aims to achieve sustained above-market growth rates through innovation and cross-selling synergies [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's long-term plans and positive trajectory despite challenges such as tariffs and currency fluctuations [14][17] - The company expects 2026 to be another year of strong execution, with revenue guidance of $2.31 billion to $2.37 billion, reflecting mid-single-digit organic growth [18] - Management highlighted the importance of disciplined capital allocation and plans to reduce debt while investing in growth [54] Other Important Information - The company recorded a non-cash technical impairment of goodwill of $501 million, which does not impact liquidity or future operations [14] - The company plans to showcase new product innovations at the upcoming AAOS conference [10] Q&A Session Summary Question: Free cash flow conversion improvements - Management indicated that operational improvements and reduced integration-related costs will drive the expected increase in free cash flow conversion to 25% in 2026 [24][25] Question: ARVIS growth expectations - Management is excited about the phased rollout of ARVIS, aiming for domestic launch in the first half of 2026 and international rollout in the second half [27] Question: U.S. hip and knee business growth - Management expects the hip and knee expansion to benefit from new product launches and competitive conversions, with a focus on commercial execution [31] Question: Sustainability of PNR growth - Management believes there is significant opportunity for continued growth in the PNR segment, supported by geographic expansion and new product introductions [56] Question: Strategic synergies between segments - Management emphasized the importance of optimizing investments and collaboration between Recon and PNR segments to enhance commercial execution and operational efficiency [71][72]

Financial Data and Key Metrics Changes - The company reported fourth quarter sales of $576 million, reflecting a 3% increase year-over-year on a reported basis and 2% organic growth [12] - For the full year, sales reached $2.2 billion, representing a 7% reported growth, with organic growth of 6% [12][13] - Adjusted gross margins improved to 61%, an increase of 170 basis points, while adjusted EBITDA margin remained flat at 17.9% [13][17] - The company returned to positive free cash flow of $20 million in 2025, with a free cash flow conversion of 10% [8][17] Business Line Data and Key Metrics Changes - Organic revenue growth was 6%, with Recon achieving 8% organic growth, while Prevention and Recovery (PNR) grew 4% [7][12] - In the fourth quarter, Recon grew 3% organically, while PNR was flat [8] - U.S. Recon experienced 6% organic growth in 2025, driven by double-digit growth in extremities [8][9] - Internationally, Recon grew 10% organically, with high single-digit growth in hips and knees [9] Market Data and Key Metrics Changes - The market for Prevention and Recovery is believed to be growing closer to 2%, while the company achieved 4% organic growth in this segment [7] - The company noted that the fourth quarter had four fewer selling days than the prior year, impacting organic growth by 400 basis points [8] Company Strategy and Development Direction - The company is focused on three key priorities: commercial execution, operational excellence, and financial discipline [5] - The "One Enovis" operating mindset aims to improve performance and standardize commercial processes across the organization [6] - The company plans to continue driving innovation, with a robust pipeline of new product introductions planned for the next 24 months [10][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's long-term plans and positive trajectory despite a dynamic operating environment [14] - The company expects 2026 to be another year of strong execution, with revenue guidance in the range of $2.31 billion to $2.37 billion [18] - Adjusted EBITDA is expected to improve by 50 basis points compared to the prior year, with a focus on driving gross margin improvements [19] Other Important Information - The company recorded a non-cash technical impairment of goodwill of $501 million, which does not impact liquidity or future operations [14] - The company is targeting a free cash flow conversion of 25% or more in 2026, with a pathway to 70%-80% in the future [25][33] Q&A Session Summary Question: Free cash flow conversion improvements - Management highlighted operational improvements and reduced integration-related costs as key drivers for the expected increase in free cash flow conversion [24][25] Question: ARVIS growth expectations - Management is excited about the rollout of ARVIS, expecting domestic rollout in the first half and international rollout in the second half of 2026 [27] Question: U.S. hip and knee business performance - Management indicated that the hip and knee expansion, along with ARVIS, could drive growth above the current range [31] Question: Cash flow and 510(k) filings - Management expects continued incremental improvements in cash flow conversion, despite the need for investments related to ARVIS [33] Question: Q4 cadence issues - Management clarified that Q4 performance was impacted by fewer selling days and did not reflect underlying market changes [36] Question: Gross margin sustainability - Management expects gross margins to continue improving due to positive product mix and productivity initiatives [39] Question: Strategic synergies between segments - Management emphasized the importance of collaboration and optimizing investments across business units to exploit synergies [71] Question: Portfolio shaping and divestitures - Management acknowledged the need for SKU rationalization and portfolio shaping to enhance growth and margin profiles [87]

Financial Data and Key Metrics Changes - The company reported fourth quarter sales of $576 million, reflecting a 3% increase year-over-year on a reported basis and 2% organic growth [11] - For the full year, sales reached $2.2 billion, representing a 7% reported growth, with organic growth of 6% [11][12] - Adjusted gross margins improved to 61%, an increase of 170 basis points, while adjusted EBITDA margin remained flat at 17.9% [12][15] - Adjusted earnings per share rose to $3.30, a 16% increase driven by gross margin expansion and reduced interest expenses [12] Business Line Data and Key Metrics Changes - The Recon segment achieved 8% organic growth, outperforming the market, while the Prevention and Recovery (PNR) segment grew 4% organically [5][11] - In the fourth quarter, Recon grew 3% and PNR was flat, impacted by four fewer selling days compared to the previous year [6][11] - The U.S. Recon segment grew 6% organically, with double-digit growth in extremities and solid performance in hips and knees [6][8] Market Data and Key Metrics Changes - Internationally, Recon grew 10% organically, with high single-digit growth in hips and knees and double-digit growth in extremities [8] - The company noted that the market for Prevention and Recovery is growing closer to 2%, while they achieved 4% organic growth in this segment [5] Company Strategy and Development Direction - The company is focused on three key priorities: commercial execution, operational excellence, and financial discipline, aiming to build a more profitable and capital-efficient growth engine [4][5] - A "One Enovis" operating mindset is being embraced to improve performance and standardize commercial processes [5] - The company plans to continue driving innovation, with a robust pipeline of new product introductions planned for the next 24 months [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's long-term plans and positive trajectory despite a dynamic operating environment [13] - The company expects 2026 to be another year of strong execution, with revenue guidance of $2.31 billion to $2.37 billion, reflecting mid-single-digit organic growth [17] - Management highlighted the importance of disciplined capital allocation and the goal of reducing debt while supporting growth initiatives [55] Other Important Information - The company returned to positive free cash flow of $20 million in 2025, with a target of over 25% free cash flow conversion in 2026 [6][16] - A non-cash technical impairment of goodwill of $501 million was recorded, but it does not impact liquidity or future operations [13] Q&A Session Summary Question: Free cash flow conversion improvements - Management indicated that operational improvements and reduced integration-related costs will drive the expected increase in free cash flow conversion [21][22] Question: ARVIS growth expectations - The rollout of ARVIS is planned in phases, with domestic launch in the first half of 2026 and international rollout in the second half [25][26] Question: U.S. hip and knee business outlook - Management expressed optimism about the hip and knee expansion, particularly with new product launches like Nebula and OrthoDrive [30] Question: Cash flow conversion trajectory - Management expects continued incremental improvements in cash flow conversion over the next several years, despite some initial investments required for new product launches [32] Question: Market dynamics and Q1 expectations - Management noted that Q1 2026 will have fewer selling days, but overall business performance is expected to align with expectations [35][37] Question: Gross margin sustainability - Management anticipates further gross margin improvements driven by product mix and productivity initiatives [39][40] Question: Portfolio shaping and divestitures - Management acknowledged the need for ongoing portfolio shaping, including SKU rationalization and potential divestitures to enhance growth and margin profiles [91][92]

Financial Data and Key Metrics Changes - The company reported high single-digit growth in the first half of the year and generated cash in the second quarter, indicating progress towards set goals [20][21] - EBITDA margins are targeted to exceed 20% for sustainable positioning as a med tech company, with current margins at 17% to 18% [16][19] Business Line Data and Key Metrics Changes - The company aims for high single-digit growth in the recon segment and stable low single-digit growth in the PNR segment, with potential for double-digit growth in recon in 2025 [22][28] - New product launches, including the ARG system and MANIFUSE, are expected to drive growth in both recon and PNR segments [27][24] Market Data and Key Metrics Changes - Market trends show a stable environment with a pickup in the U.S. and a slight slowdown in Europe due to seasonal factors, but overall conditions are expected to stabilize [21] - The company has seen a shift in international sales from 22% to over 50% in the recon segment following the Lima acquisition [50] Company Strategy and Development Direction - The company is focusing on organic growth, operational excellence, and capital allocation, with a priority on debt reduction and free cash flow improvement [6][8][42] - The management emphasizes a robust product pipeline and innovation, aiming for a mix of singles and doubles rather than home runs [11][75] Management's Comments on Operating Environment and Future Outlook - Management acknowledges macroeconomic uncertainties as a wildcard affecting growth, particularly in Europe and Asia [33][28] - The company expects to be free cash flow positive in 2025, with a clear path to achieving 70% to 80% free cash conversion by 2026 [29][30] Other Important Information - The company plans to mitigate tariff impacts by shifting sourcing from China and increasing prices on the PNR side [37][39] - The ARVIS platform launch has been delayed by six months, but it is expected to enhance growth in the recon segment once fully operational [48][63] Q&A Session Summary Question: What are the business trends in July and August? - The company experienced high single-digit growth in the first half and anticipates stable market conditions for the third quarter [20][21] Question: Is there a pathway to double-digit recon growth in 2025? - The company believes it can achieve double-digit growth in recon, depending on new product launches and market conditions [22][23] Question: What are the key metrics for driving shareholder value? - The focus will be on meeting growth commitments, expanding EBITDA, and improving free cash flow [19] Question: What are the trends in the PNR market? - The PNR segment has shown resilience with stable growth of 3% to 4%, contributing significantly to cash generation [67] Question: What is the company's approach to capital allocation? - The immediate focus is on debt reduction, with M&A activities being deprioritized for the time being [42][46] Question: How will ARVIS contribute to revenue? - ARVIS is expected to start contributing meaningfully to revenues within a year, with initial contributions already noted [63] Question: What are the expectations for growth in 2026? - The company anticipates stable growth in recon and PNR, with potential headwinds from macroeconomic factors [31][33]

Financial Data and Key Metrics Changes - The company reported second quarter sales of $565 million, up 7% year-over-year and 5% on an organic basis, with approximately 200 basis points of positive currency tailwinds offset by a similar headwind from selling days [21][22][25] - Adjusted gross margins improved by 90 basis points in the quarter and 200 basis points year-to-date, driven by favorable segment and product mix [22] - Adjusted EBITDA margins were flat at 17.2% year-over-year, with year-to-date adjusted EBITDA margins expanding by 75 basis points [23][24] - Adjusted earnings per share increased by 27% year-over-year to $0.79, with first half adjusted EPS growing 42% [23][24] Business Line Data and Key Metrics Changes - The recon business saw organic growth of 8%, with U.S. extremities growing by 10% driven by strong double-digit growth in shoulders [14][21] - The P and R segment experienced stable growth of 3% in the quarter, with adjusted EBITDA margins improving by 130 basis points year-over-year [19][22] - U.S. hip and knee growth was flat, reflecting fewer selling days and headwinds in capital sales, but underlying implant growth was mid-single digit [16][22] Market Data and Key Metrics Changes - U.S. extremities growth was driven by the launch of the augmented reverse glenoid system, while international growth benefited from recent geographical expansion [15][17] - The company continues to take share in resilient international markets, with competitive share gains in hip and shoulder portfolios [17][18] Company Strategy and Development Direction - The company aims to focus on three key priorities: commercial execution and innovation, operational excellence, and financial discipline [10][12] - There is a commitment to maximizing organic growth, margin expansion, and cash flow generation through disciplined capital allocation [7][10] - The company plans to leverage its diverse portfolio and capitalize on cross-selling opportunities to drive growth [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the evolving market environment and maintain progress towards strategic goals [28] - The company anticipates acceleration in growth in the second half of the year, particularly with new product launches [16][22] - Management highlighted the importance of relationships with key opinion leaders and the commitment to medical education as critical to maintaining market leadership [82] Other Important Information - The company raised its revenue guidance for 2025 to a range of $2.245 billion to $2.275 billion, driven by improved currency outlook and organic growth execution [25][26] - The adjusted EBITDA range was also raised to $392 million to $400 million, reflecting an updated view on tariffs [26][27] - The company paid $6 million in tariffs in Q2, primarily related to the P and R segment, with expectations for mitigation efforts to accelerate through the year [27][28] Q&A Session Summary Question: What are the assumptions for ARVIS in the back half and other new products driving growth? - Management noted that the Nebula hip and ARG for shoulder are expected to drive growth in the back half, with positive early feedback from the market [32][33] Question: Concerns about adjusted EBITDA metrics and free cash flow normalization? - Management reassured that they maintain high standards of transparency and are confident in their adjusted EBITDA metrics, with expectations for improved free cash flow as integration costs decrease [36][39] Question: Insights on M&A strategy post-Lima and balancing debt paydown with acquisitions? - The focus is on debt reduction as the primary capital allocation priority, with potential for opportunistic share buybacks or focused M&A in the future [47] Question: Updates on the ARVIS shoulder launch and its importance? - The ARVIS launch has received tremendous feedback, and the next-gen updates are expected to enhance market share gains in the shoulder portfolio [74] Question: Competitive dynamics in the shoulder market and maintaining market leadership? - Management emphasized the importance of relationships, commercial execution, and new product releases to maintain and grow market share [81][85]